Tests a medicine to prevent weight gain in young adults
Tests Qsymia or placebo in adolescents and young adults at high risk of weight gain.
Plain-language title generated from the registry record
Registry title: Weight Gain Prevention in Adolescents and Young Adults
Key facts
- Where
- Minneapolis, United StatesSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 25 years old?
Source: NCT06905626, who can take part
Where in United States
- University of Minnesota, Center for Pediatric Obesity MedicineMinneapolis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Minnesota
- Trial code
- NCT06905626
- Record updated
- 4 November 2026
- Original description
The investigators believe they key to effective prevention of obesity is early identification of individuals at high risk of excess weight gain and proactive implementation of a comprehensive approach including lifestyle-based coaching and preventive medical management targeting the pathophysiology of dysregulated energy metabolism. In this study the investigators will take a fundamentally different approach to the science of obesity prevention by targeting the underlying biological processes driving unhealthy weight gain in adolescents/young adults (AYAs), a group that has been underrepresented in medication trials.Read full original descriptionShow less
Prevention of Obesity in Adolescents and Young Adults
The investigators believe they key to effective prevention of obesity is early identification of individuals at high risk of excess weight gain and proactive implementation of a comprehensive approach including lifestyle-based coaching and preventive medical management targeting the pathophysiology of dysregulated energy metabolism. In this study the investigators will take a fundamentally different approach to the science of obesity prevention by targeting the underlying biological processes driving unhealthy weight gain in adolescents/young adults (AYAs), a group that has been underrepresented in medication trials.
Inclusion: Age 18 to M 25 at screening; BMI >/= 25 to < 30 kg/m\^2; Family history of obesity defined as one biological parent with severe obesity (BMI >/= 35) and/or two biological parents with obesity (BMI >/=30). Parental obesity status will be confirmed by obtaining a release of information to review and electronic health record.
Exclusion: Current or recent (<6 months prior to screening) use of anti-obesity medication(s) or other weight-altering medication(s) (e.g. atypical anti-psychotics, attention deficit hyperactivity disorder (ADHD) stimulant); Previous bariatric surgery; Current or recent (<6 months prior to screening) use of medication(s) to treat insulin resistance; Recent initiation (<3 months prior to screening) of anti-hypertensive or lipid medication(s); Current or recent (<14 days prior to screening) use of monoamine oxidase inhibitor; History of treatment with growth hormone; Diabetes (type 1 or 2); History of glaucoma; Known hypersensitivity to sympathomimetic amines; Eating disorder symptoms within 6 months and/or any past medical diagnosis of eating disorder; Major psychiatric disorder; History of suicide attempt; History of seizures; Uncontrolled hypertension; History of structural heart defect; History of clinically significant arrhythmia; History of cholelithiasis; History of nephrolithiasis; Untreated thyroid disorder; Alanine transaminase (ALT) or aspartate transaminase (AST) >/= 2.5 times the upper limit of normal; Bicarbonate 18 mmol/L; Creatinine > 1.2 mg/dL; Creatinine clearance <50 mL/min (Schwartz formula); Tanner stage 1-4; Patient Health Questionnaire-9 (PHQ-9) score of >/= 15 at screening; Unstable clinically-diagnosed depression; Suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) at any time during the study; Current pregnancy or breastfeeding; Plans to become pregnant; If sexually active, refusal to use 2 forms of birth control; Tobacco use; Diagnosed monogenic obesity; Hyperthyroidism.